about
Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human diseaseTherapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseasesInhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingOverexpression of Ribosomal RNA in the Development of Human Cervical Cancer Is Associated with rDNA Promoter HypomethylationThe pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma.A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes.Strategies to Inhibit Myc and Their Clinical ApplicabilityEffect of low doses of actinomycin D on neuroblastoma cell linesDefining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growthAmino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcriptionThe Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Up-regulation of ribosome biogenesis by MIR196A2 genetic variation promotes endometriosis development and progression.Maf1, A New PTEN Target Linking RNA and Lipid Metabolism.Proteome complexity and the forces that drive proteome imbalance.TIF-IA: An oncogenic target of pre-ribosomal RNA synthesis.Molecular Structures of Transcribing RNA Polymerase I.Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.MXD1 localizes in the nucleolus, binds UBF and impairs rRNA synthesis.Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.[Ribosomes synthesis at the heart of cell proliferation].Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer.MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children’s oncology group.
P2860
Q26785508-20C3A8F2-E7BA-471B-8D23-F3CCC37145DAQ27005780-01FDBA9F-2D58-400E-BB11-6FA812A8BD1FQ28071309-5F5FEAF7-E8ED-47B1-93A9-896813F5BA5AQ28468631-6E020F43-6378-484C-A4BA-A49FC01FE56DQ28554451-62A98A9F-EE07-4949-8B33-539D2FEC9907Q33884719-11F5F1E8-AFC6-4330-9282-995CB5068708Q34042569-B6C97B10-3C85-4295-89BB-7F05E6D229EDQ36303678-062C3C16-4EDA-42E1-8883-5E0409770B85Q36423770-D33DA433-800E-41AF-A142-87690070C88CQ37264327-8E2659AD-7F04-44D3-AF1D-BEC5FCE148FBQ37580133-6E50974E-92DC-46A0-91B8-F7B6A6B74191Q37631697-4A5B562F-980A-4829-B6CC-E46E5A9E7990Q37718273-29F08ABB-D9F0-455A-A194-2277AD3880DCQ38863765-DCD9CAFC-BD26-4650-899E-4831D680F9F5Q38954697-A7725A71-4351-4127-B064-1157C135E63CQ38958112-C557EA37-4151-4219-84AF-225097C6DA75Q39720305-77426281-A342-4443-BF0C-2BBBB1BEC350Q41186543-9F23A3F2-80BA-4F5B-BFE2-00E24A4DE580Q41889733-325DACCA-4BE4-4D8B-B8A4-919998D0880AQ45070718-EECAFE10-E6FD-4157-89E3-D39FE5828E5AQ49485824-1FA5DEBA-ACCE-4E30-8748-B12E07656117Q49706804-AB7DB1B2-9057-4091-888A-112BE82586E7Q50019647-0897C1F4-AE9E-435E-BCD8-9B933C93EE32
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting RNA polymerase I to treat MYC-driven cancer.
@en
type
label
Targeting RNA polymerase I to treat MYC-driven cancer.
@en
prefLabel
Targeting RNA polymerase I to treat MYC-driven cancer.
@en
P2860
P356
P1433
P1476
Targeting RNA polymerase I to treat MYC-driven cancer
@en
P2093
G Poortinga
P2860
P2888
P304
P356
10.1038/ONC.2014.13
P407
P577
2014-03-10T00:00:00Z
P5875
P6179
1002318019